A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

Phase 2/3 Completed 90 enrolled Abbott Abbott Japan Co.,Ltd · collab Eisai Inc. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.

Timeline

Start: 2007-02
Primary completion: 2007-12
Completion: —

Publications

Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam MS, Camez A; Study Investigators. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis. 2012 Mar;6(2):160-73. doi: 10.1016/j.crohns.2011.07.013. Epub 2011 Aug 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adalimumab	Monoclonal antibody	40 mg	—
Subject	Adalimumab	Monoclonal antibody	80 mg	—

A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

Summary

Timeline

Publications

Drugs

Indications